Bedrijfsoverzicht
Cosmos Health Inc. is a specialized entity within the healthcare sector, specifically operating in the medical distribution industry, where it focuses on the manufacturing, development, and trade of branded nutraceutical products across a diverse geographic footprint including Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company's product portfolio encompasses a comprehensive range of items such as prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics, and related health products. As of the latest available data, the enterprise holds a market capitalization of $11.20M and employs a workforce of 149 individuals to support its operational activities. With an annual revenue of $59.79M, the company operates on a micro-cap scale, which indicates a niche market position rather than broad market dominance. This relatively small market cap combined with the specific revenue figure suggests that the business is a specialized player rather than a large-cap competitor, reflecting its focused approach to serving specific regional markets with its distinct product offerings.
Financiële gezondheid
The company reported total revenue of $59.79M over the trailing twelve months, yet this top-line performance is offset by a net income loss of $18,542,138, revealing a significant structural cost burden or expense recognition that heavily impacts the bottom line. This disparity between revenue and net income highlights a challenging cost structure where operating expenses or losses from discontinued operations likely exceed gross profits, resulting in a net income that is substantially negative relative to sales. Further deepening the financial strain, the entity recorded an EBITDA of $-12,621,250, indicating that even before interest and taxes, the core business operations are currently generating negative cash earnings. Liquidity remains constrained as the free cash flow stands at $-5,310,300, which implies a lack of financial flexibility to fund expansion without external capital injections or access to credit markets. The margin profile underscores these operational challenges, with a gross margin of 11.4%, an operating margin of -10.6%, and a profit margin of -31.0%, showing that while the cost of goods sold is moderate, operating inefficiencies or other expenses are eroding profitability significantly. On the balance sheet, cash holdings of $922,619 are vastly outweighed by total debt of $21.07M, creating a precarious liquidity situation exacerbated by a debt-to-equity ratio of 91.08%. This high leverage level indicates that the company is heavily indebted relative to its equity base, suggesting a balance sheet that is highly leveraged rather than conservative. Short-term solvency is further tested by a current ratio of 0.99, which indicates that current assets are insufficient to cover current liabilities without the need to liquidate assets or secure new financing. Finally, the return metrics reflect the financial distress, with a return on equity of -63.8% and a return on assets of -13.0%, demonstrating that management has been unable to generate positive returns on the capital invested or assets utilized during the reporting period.
Waarderingsbeoordeling
Valuation metrics for Cosmos Health Inc. present a complex picture due to the lack of positive earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -2.73. The absence of a trailing P/E implies that earnings are negative, while the negative forward P/E suggests that analysts or the market expects earnings to remain negative in the near future. Asset-based valuation is possible given a price-to-book ratio of 0.41, which indicates that the market values the company at less than half of its book value, suggesting a significant discount relative to the underlying net asset value. Alternative valuation multiples provide further insight into the market's pricing, with a price-to-sales ratio of 0.19 and an EV/EBITDA of -2.43, both of which reflect the market's pricing of the company based on sales volume and enterprise value rather than profitability. The stock's price volatility is evident from its trading range, with a 52-week high of $1.32 and a 52-week low of $0.28. Based on the provided data points, the current price sits below the 52-week high, though the exact percentage depends on the specific share price not explicitly defined as a single static number in the source text, the range demonstrates significant price swings within the last year. The beta of 4.46 is exceptionally high, indicating that the stock price is highly volatile and tends to move with much greater intensity than the broader market, amplifying both potential gains and potential losses for holders.
Growth & Income
Cosmos Health Inc. demonstrates strong top-line expansion with a revenue growth rate of 37.9% year-over-year, while earnings growth is listed as N/A due to the company's consistent net losses. The divergence between robust revenue growth and negative earnings suggests that the company is prioritizing market share expansion or inventory buildup over immediate profitability, or that costs are rising faster than sales. Regarding income generation, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings—or in this case, retains losses—into growth initiatives rather than distributing cash to shareholders. This strategy is typical for early-stage or turnaround companies that require capital retention to fund operations and expansion plans despite current unprofitability. Overall, the growth and income profile is characterized by aggressive sales expansion paired with a complete absence of current earnings power and dividend distribution.